Condition
Large Cell Neuroendocrine Carcinoma of the Lung
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 11 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
11 shownPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid TumorsNCT07006727 · 2025-10-16
RECRUITINGRadiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsNCT06814496 · 2025-09-08
RECRUITINGFIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumNCT06393816 · 2024-06-13
RECRUITINGA Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the LungNCT07561645 · 2026-09-01
NOT_YET_RECRUITINGStudy of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based ChemotherapyNCT06736418 · 2025-03-10
ACTIVE_NOT_RECRUITINGDLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung CancerNCT05680922 · 2023-07-26
ACTIVE_NOT_RECRUITINGA Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the LungNCT05470595 · 2022-01-18
ACTIVE_NOT_RECRUITINGTargeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLCNCT04010357 · 2020-01-13
COMPLETEDAtezolizumab in Large Cell Neuroendocrine CarcinomaNCT06049966 · 2019-11-01
COMPLETEDPembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaNCT03901378 · 2019-10-02
WITHDRAWNuPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the LungNCT02755675 · 2016-04-01
UNKNOWNCommon interventions
AtezolizumabDRUG2111In-ETN029DRUG1225Ac-ABD147DRUG1225Ac-ETN029DRUG168Ga-NOTA-AE105 PET/CTOTHER1Abemaciclib,DRUG1CarboplatinDRUG1Concurrent Radiation TherapyRADIATION1Durvalumab with etoposide and Carboplatin/CisplatinDRUG1EtoposideDRUG1LB2102BIOLOGICAL1ObrixtamigDRUG1PembrolizumabDRUG1Sequential Radiation therapyRADIATION1TarlatamabDRUG1
Leading sponsors
Technische Universität Dresden
2
Abdera Therapeutics Inc.
1
Case Comprehensive Cancer Center
1
Centre Leon Berard
1
Copenhagen University Hospital, Rigshospitalet
1
Legend Biotech USA Inc
1
Novartis Pharmaceuticals
1
Ochsner Health System
1
Oncology Center of Biochemical Education And Research
1
University of Arizona
1
Trial status mix
ACTIVE_NOT_RECRUITING3
RECRUITING3
COMPLETED2
NOT_YET_RECRUITING1
UNKNOWN1
WITHDRAWN1
Phase mix
PHASE27
PHASE15
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.